Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Long-Long Gao et al.|The Lancet|2022Cited by 295
P651 Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experienceHarland S. Winter, Jeffrey S. Hyams, James Izanec et al.|Journal of Crohn s and Colitis|2019Cited by 0